Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00075 / http://dx.doi.org/10.20960/revcancer.00075

Resumen| PDF

Revisión

Preservación de órgano en tumores de cabeza y cuello

María Aguado Sorolla, Óscar Gallego Rubio, Antonio López-Pousa

Prepublicado: 2024-05-16

Publicado: 2024-07-03

VOLUMEN 38, NÚM. 2, marzo-abril (2024), PAG. 47-53

Logo Descargas Número de descargas: 10962 Logo Visitas Número de visitas: 574 Citas Citas: 0

Compártelo:

El carcinoma escamoso de cabeza y cuello (CECC) representa un 5 % de todos los tumores y hasta el 70 % de los casos se diagnostica en estadios localmente avanzados. La aproximación terapéutica actual apoya el uso de estrategias de preservación funcional de órgano. La quimioterapia concomitante con radioterapia (QTRTc) con esquema de cisplatino (CDDP) trisemanal a dosis altas es la más ampliamente usada. Pueden valorarse otras estrategias con distintas posologías de CDDP, esquemas con carboplatino (CBDCA) o cetuximab, en función de las comorbilidades del paciente. Los esquemas con quimioterapia de inducción tienen un papel controvertido en la actualidad. Se han intentado estrategias de desescalada en tumores con virus del papiloma humano (VPH) positivo, por el momento sin éxito. Actualmente se encuentran en estudio nuevas moléculas que puedan sumar beneficio a la QTRTc.

Palabras Clave: Quimioterapia. Radioterapia. Inducción. Localmente avanzado. Cisplatino. Virus del papiloma humano.

Descargar PDF

Bibliografía
Artículos Relacionados

National Comprehensive Cancer Network. Head and Neck Cancers (Version 3.2024). Available from: www.nccn.org/professionals/ physician_gls/pdf/head-and-neck.pdf

Mesia R, Iglesias L, Lambea J, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol 2021;23(5):913-921.
DOI: 10.1007/s12094-020-02533-1

Grégoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcino- ma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Supl. 5):184-6.
DOI: 10.1093/annonc/mdq185

Chinn SB, Myers JN. Oral cavity carcinoma: Current man- agement, controversies, and future directions. J Clin Oncol 2015;33(29):3269-76.
DOI: 10.1200/JCO.2015.61.2929

Mesía R, Pastor M, Cruz JJ, et al. SEOM clinical guidelines for the treatment of head and neck cancer. Clin Transl Oncol 2010;12:742- 8.
DOI: 10.1007/s12094-010-0589-2

Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: issues and outcomes. J Clin Oncol 2015;33(29):3262-8.
DOI: 10.1200/JCO.2015.61.2978

Department of Veterans Affairs Laryngeal Cancer Study Group; Wolf GT, Fisher SG, Hong WK, et al. Induction chemo- therapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685.
DOI: 10.1056/NEJM199106133242402

Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592.
DOI: 10.1200/JCO.1994.12.8.1592

Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation thera- py for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1998;91:2081-6.
DOI: 10.1093/jnci/91.24.2081

Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemother- apy and radiotherapy for organ preservation in advanced laryn- geal cancer. N Engl J Med 2009;349:2091-8.
DOI: 10.1056/NEJMoa031317

Wong SJ, Harari PM, Garden AS. Longitudinal Oncology Regis- try of Head and Neck carcinoma (LORHAN): analysis of chemo- radiation treatment approaches in the United States. Cancer 2011;117(8):1769-86.
DOI: 10.1002/cncr.25721

Al-Sarraf. The role of concurrent chemo-radiotherapy in patients with head and neck cancers: a review. Gulf J Oncolog 2007Jul:(2):8-16.

Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcino- ma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949.
DOI: 10.1016/S0140-6736(00)90011-4

Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemother- apy in head and neck cancer (MACH-NC): an update on 93 ran- domised trials and 17,346 patients. Radiother Oncol 2009;92(1):4.
DOI: 10.1016/j.radonc.2009.04.014

Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 rand- omized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281.
DOI: 10.1016/j.radonc.2021.01.013

Laszlo A, Rosset A, Hermann F, et al. T.i.d. radiotherapy with or with- out alternating chemotherapy in patients with a locally advanced squamous cell carcinoma of the head and neck: An analysis of late toxicity. Cancer Radiother 2001;52:130-7.
DOI: 10.1016/S1278-3218(01)00085-3

Chen LY, Huang CC, Tsou Ya, et al. Prognostic factor of severe com- plications in patients with hypopharyngeal cancer with primary concurrent chemoradiotherapy. Anticancer Res 2015;35(3):1735-41.

Sharma A, Kumar M, Bhasker S, et al. An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial). J Clin Oncol 2022;40;16S.

Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck

Bourhis J, Sire C, Graff P. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemo- therapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13(2):145-53.
DOI: 10.1016/S1470-2045(11)70346-1

Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemora- diation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007;43:1399.
DOI: 10.1016/j.ejca.2007.03.022

Tao Y, Auperin A, Sire C, et al. Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. J Clin Oncol 2018:JCO2017762518.
DOI: 10.1200/JCO.2017.76.2518

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567.
DOI: 10.1056/NEJMoa053422

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year sur- vival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21.
DOI: 10.1016/S1470-2045(09)70311-0

Department of Veterans Affairs Laryngeal Cancer Study Group; Gregory T Wolf, Susan Gross Fisher, Waun Ki Hong, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
DOI: 10.1056/NEJM199106133242402

Hitt R, Lopez-Pousa A, Martínez Trufero, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradio- therapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45.
DOI: 10.1200/JCO.2004.00.1990

Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-52.
DOI: 10.1200/JCO.2012.43.6097

Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy fol- lowed by concurrent chemoradiotherapy (sequential chemoradiother- apy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257-64.
DOI: 10.1016/S1470-2045(13)70011-1

Cohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 local- ly advanced head and neck cancer. J Clin Oncol 2014;32:2735.
DOI: 10.1200/JCO.2013.54.6309

Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 2017;28:2206-12.
DOI: 10.1093/annonc/mdx299

Geoffrois L, Martin L, De Raucourt D, et al. Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. J Clin Oncol 2018;36:3077-88.
DOI: 10.1200/JCO.2017.76.2591

Janoray G, Pointreau Y, Garaud P, et al. Long-term results of GORTEC 2000-01: A multicentric randomized phase III tri- al of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation. J Clin Oncol 2015;33;15(Supl):6002.
DOI: 10.1200/jco.2015.33.15_suppl.6002

Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluoro- uracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;25;357:1695-704.
DOI: 10.1056/NEJMoa071028

Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluoro- uracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
DOI: 10.1056/NEJMoa070956

Kiyota N, Tahara M, Mizusawa J, et al. Weekly Cisplatin Plus Radi- ation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. J Clin Oncol 2022;40(18):1980-90.
DOI: 10.1200/JCO.21.01293

Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 2004;58:1418- 23.
DOI: 10.1016/j.ijrobp.2003.09.004

Hitchcock YJ, Bentz BG, Sharma PK, et al. Planned neck dissec- tion after definitive radiotherapy or chemoradiation for base of tongue cancers. Otolaryngol Head Neck Surg 2007;137:422-7.
DOI: 10.1016/j.otohns.2007.03.008

Forest VI, Nguyen-Tan PF, Tabet JC, et al. Role of neck dissection following concurrent chemoradiation for advanced head and neck carcinoma. Head Neck 2006;28(12):1099-105.
DOI: 10.1002/hed.20479

Goguen LA, Posner MR, Tishler RB, et al. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132(5):526-31.
DOI: 10.1001/archotol.132.5.526

Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017;18(9):1221-37.
DOI: 10.1016/S1470-2045(17)30458-8

Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13(2):145-53.
DOI: 10.1016/S1470-2045(11)70346-1

Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858-66.
DOI: 10.1200/JCO.2014.55.3925

Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-posi- tive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393:51-60.
DOI: 10.1016/S0140-6736(18)32752-1

Gebre-Medhin M, Brun E, Engström P, et al. ARTSCAN III: A Ran- domized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol 2021;39(1):38-47.
DOI: 10.1200/JCO.20.02072

Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021;22(4):450-62.
DOI: 10.1016/S1470-2045(20)30737-3

Machiels J, Tao Y, Burtness B, et al. Primary results of the phase III KEYNOTE 412 study: Pembrolizumab (pembro) with chemoradia- tion therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2022;33(Suppl 7):S808-S869.
DOI: 10.1016/j.annonc.2022.08.029

Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
DOI: 10.1200/JCO.2013.53.5633

Caudell JJ, Torres-Saavedra PA, Rosenthal DI, et al. Long-Term Update of NRG/RTOG 0522: A randomized phase 3 trial of con- current radiation and cisplatin with or without cetuximab in locore- gionally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2023;116(3):533-43.
DOI: 10.1016/j.ijrobp.2022.12.015

Xu-Shan S, Thao Y, LeTourneau C, et al. Debio 1143 and high-dose cisplatin chemotherapy in high-risk locoregionally advanced squa- mous cell carcinoma of the head and neck: a double-blind, multi- centre, randomized, phase 2 study. Lancet Oncol 2020;21(9):1173- 87.
DOI: 10.1016/S1470-2045(20)30327-2

Revisión: Plataformas genómicas para decisión terapéutica del carcinoma ductal in situ de mama

Publicado: 2022-07-22 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Radioterapia en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer extrahepático de vías biliares

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Medicina de precisión y el papel de la irradiación en hepatocarcinoma

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento perioperatorio del cáncer gástrico

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF